The evolution, prevalence and challenges triggered of H1N1pdm influenza

doi:10.19871/j.cnki.xfcrbzz.2021.02.016

Abstract

Abstract: Novel pandemic H1N1 influenza A (H1N1pdm) emerged in 2009, gradually replacing the seasonal H1N1 influenza, and co-existing with H3N2 and B influenza in the epidemic seasons. Human suffering from influenza consumes considerable social medical resources and poses a great challenge to global public health. With the continuous evolution of H1N1pdm genetic molecules for more than ten years, we briefly summarized the H1N1pdm epidemic, viral pathogenicity, host adaptability, biological features, ability to replicate infection, transmission power, sensitive drugs and effective vaccines. Understanding H1N1pdm epidemic, and evolution, was be conducive to raising people's vigilance against the pandemic caused by pathogen variations of novel infectious diseases such as influenza, and to providing a reference for clinical and public health prevention and control.

Key words: Influenza A, Evolution, Prevalence, Challenges

Tan Jing, Huang Xiaoling, Huang Ping. The evolution, prevalence and challenges triggered of H1N1pdm influenza[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(2): 146-150.

References

[1] DAWOOD FS, JAIN S, FINELLI L, et al.Emergence of a novel swine-origin influenza A(H1N1) virus in humans[J]. N Engl J Med, 2009, 360(25):2605-2615.
[2] BEDFORD T, RILEY S, BARR IG, et al.Global circulation patterns of seasonal influenza viruses vary with antigenic drift[J]. Nature, 2015, 523(7559):217-220.
[3] SHAO W, LI X, GORAYA M, et al.Evolution of Influenza A Virus by Mutation and Re-Assortment[J]. Int J Mol Sci, 2017, 18(8):1650.
[4] TAUBENBERGER JK, KASH JC, MORENS DM. The1918 influenza pandemic: 100 years of questions answered and unanswered[J]. Sci Transl Med, 2019, 11(502):eaau5485.
[5] LYONS DM, LAURING AS.Mutation and Epistasis in Influenza Virus Evolution[J]. Viruses, 2018, 10(8):407.
[6] PINSENT A, FRASER C, FERGUSON NM, et al.A systematic review of reported reassortant viral lineages of influenza A[J]. BMC Infect Dis, 2016, 16:3.
[7] 苏伟,张复春. 甲型流感研究进展[J/CD]. 新发传染病电子杂志,2018,3(3):140-142.
[8] KULKARNI SV, NARAIN JP, GUPTA S, et al.Influenza A(H1N1) in India: Changing epidemiology and its implications[J]. Natl Med J India, 2019, 32(2):107-108.
[9] 李航,鲁植艳. 美国近期严重流感疫情引发的思考[J/CD]. 新发传染病电子杂志,2018,3(1):5-7.
[10] WANG Y, WANG X, LIU X, et al.Epidemiology of Imported Infectious Diseases, China, 2005-2016[J]. Emerg Infect Dis, 2018, 25(1):33-41.
[11] MA Y, LIU K, YIN Y, et al.The Phylodynamics of Seasonal Influenza A/H1N1pdm Virus in China Between 2009 and 2019[J]. Front Microbiol, 2020, 11:735.
[12] KETLAO S, BOONARKART C, PHAKARATSAKUL S, et al.Responses to the Sb epitope contributed to antigenic drift of the influenza A 2009 H1N1 virus[J]. Arch Virol, 2020, 165(11):2503-2512.
[13] 梁丽君, 钟静, 黄平, 等. 广东新型甲型H1N1病毒血凝素基因分子进化与变异[J]. 中华微生物学和免疫学杂志, 2013(3):173-177.
[14] SKOWRONSKI DM, CHAMBERS C, SABAIDUC S, et al.Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season[J]. J Infect Dis, 2015, 212(5):726-39.
[15] RETAMAL M, ABED Y, RHEAUME C, et al.In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site[J]. J Gen Virol, 2017, 98(6):1224-1231.
[16] WORLD HEALTH ORGANIZATION(WHO). Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season[J]. Wkly Epidemiol Rec, 2017, 92(11):117-128.
[17] CHEN Y, BAI T, ZHU W, et al.The S190R mutation in the hemagglutinin protein of pandemic H1N1 2009 influenza virus increased its pathogenicity in mice[J]. Sci China Life Sci, 2018, 61(7):836-843.
[18] TU V, ABED Y, FAGE C, et al.Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses[J]. Antiviral Res, 2018, 154:110-115.
[19] NOGALES A, MARTINEZ-SOBRIDO L, CHIEM K, et al.Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans[J]. J Virol, 2018, 92(19):e01206-18.
[20] GARRETSON TA, PETRIE JG, MARTIN ET, et al.Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain[J]. Vaccine, 2018, 36(28):4095-4101.
[21] ZHANG Y, ZHANG Q, GAO Y, et al.Key molecular factors in hemagglutinin and PB2 contribute to efficient transmission of the 2009 H1N1 pandemic influenza virus[J]. J Virol, 2012, 86(18):9666-9674.
[22] JONES S, NELSON-SATHI S, WANG Y, et al.Evolutionary, genetic, structural characterization and its functional implications for the influenza A (H1N1) infection outbreak in India from 2009 to 2017[J]. Sci Rep, 2019, 9(1):14690.
[23] KLEIN EY, BLUMENKRANTZ D, SEROHIJOS A, et al.Stability of the Influenza Virus Hemagglutinin Protein Correlates with Evolutionary Dynamics[J]. mSphere, 2018, 3(1):e00554-17.
[24] WEN F, LI L, ZHAO N, et al.A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells[J]. J Virol, 2018, 92(2):e01621-17.
[25] HE W, ZHANG W, YAN H, et al. Distribution and evolution of H1N1 influenza A viruses with adamantanes‐resistant mutations worldwide from1918 to 2019[J]. J Med Virol, 2020, 10.1002/jmv.26670.
[26] SCOTT C, KANKANALA J, FOSTER TL, et al.Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza[J]. PLoS Pathog, 2020, 16(8):e1008716.
[27] HUSSAIN M, GALVIN HD, HAW TY, et al.Drug resistance in influenza A virus: the epidemiology and management[J]. Infect Drug Resist, 2017, 10:121-134.
[28] HANPAIBOOL C, LEELAWIWAT M, TAKAHASHI K, et al.Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase[J]. J Comput Aided Mol Des, 2020, 34(1):27-37.
[29] TAKASHITA E, FUJISAKI S, YOKOYAMA M, et al.In Vitro Characterization of Multidrug-Resistant Influenza A (H1N1) pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients[J]. Pathogens, 2020, 9(9):725.
[30] ABED Y, SAIM-MAMOUN A, BOIVIN G.Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini‐review[J]. Rev Med Virol, 2020, e2175
[31] GOLDHILL DH, TE VELTHUIS AJW, FLETCHER RA, et al.The mechanism of resistance to favipiravir in influenza[J]. Proc Natl Acad Sci U S A, 2018, 115(45):11613-11618.
[32] LEE LYY, ZHOU J, FRISE R, et al.Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission[J]. PLOS Pathogens, 2020, 16(4):e1008395.
[33] CHECKMAHOMED L, M'HAMDI Z, CARBONNEAU J, et al. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains[J]. J Infect Dis, 2020, 221(1):63-70.
[34] TAKASHITA E, ABE T, MORITA H, et al.Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment[J]. Antiviral Res, 2020, 180:104828.
[35] WU D, TAN Q, ZHANG H, et al.Genomic and biological features of a novel orbivirus isolated from mosquitoes, in China[J]. Virus Res, 2020, 285:197990.
[36] ZHOU P, YANG XL, WANG XG, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798):270-273.
[37] SUN W, LUO T, LIU W, et al.Progress in the Development of Universal Influenza Vaccines[J]. Viruses, 2020, 12(9):1033.
[38] PAULES C, SUBBARAO K.Influenza[J]. Lancet, 2017, 390(10095):697-708.